- $3.53bn
- $2.74bn
- $43.95m
- 41
- 11
- 80
- 40
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.73 | ||
| Price to Tang. Book | 4.74 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 100.36 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -24.29% | ||
| Return on Equity | -33.39% | ||
| Operating Margin | -560.03% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 31.13 | 29.94 | 49.11 | 41.59 | 43.95 | 32.16 | 55.61 | 2.75% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The company operates in the Netherlands and United States.
Directors
- Anand Mehra NEC (45)
- Sven Lundberg PRE (57)
- Gregory Perry NVC (60)
- Cornelis Adriaan de Kruif CTO (57)
- Peter Silverman GCN (43)
- Alexander Bakker OTH (54)
- Andrew Joe OTH (55)
- Hui Liu OTH (48)
- Mark Iwicki NID (54)
- Leonard Kanavy NID (59)
- Paolo Pucci NID (59)
- Victor Sandor NID (54)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- June 16th, 2003
- Public Since
- May 19th, 2016
- No. of Shareholders
- 190
- No. of Employees
- 172
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 68,210,479
- Address
- Uppsalalaan 17, 3rd & 4th floor, UTRECHT, 3584 CT
- Web
- https://merus.nl/
- Phone
- +31 850162500
- Contact
- Sherri Spear
- Auditors
- KPMG Accountants N V
Upcoming Events for MRUS
Q4 2024 Merus NV Earnings Release
Similar to MRUS
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Actuate Therapeutics
NASDAQ Global Market
FAQ
What is the Merus NV share price?
As of Today at 16:02 UTC, shares in Merus NV are trading at $51.78. This share price information is delayed by 15 minutes.
How has the Merus NV share price performed this year?
Shares in Merus NV last closed at $51.78 and the price had moved by +140.06% over the past 365 days. In terms of relative price strength the Merus NV share price has outperformed the S&P500 Index by +79.84% over the past year.
What are the analyst and broker recommendations for Merus NV?
The overall consensus recommendation for Merus NV is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Merus NV dividend yield?
Merus NV does not currently pay a dividend.
Does Merus NV pay a dividend?
Merus NV does not currently pay a dividend.
When does Merus NV next pay dividends?
Merus NV does not currently pay a dividend.
How do I buy Merus NV shares?
To buy shares in Merus NV you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Merus NV?
As of the previous close price of $51.78, shares in Merus NV had a market capitalisation of $3.53bn.
Where are Merus NV shares listed?
Here are the trading details for Merus NV:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: MRUS
What kind of share is Merus NV?
Based on an overall assessment of its quality, value and momentum Merus NV is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Merus NV share price forecast for 2024?
The analyst consensus target price for shares in Merus NV is $87.73. That is 69.43% above the last closing price of $51.78.
Analysts covering Merus NV currently have a consensus Earnings Per Share (EPS) forecast of -$3.18 for the next financial year.
Find out moreWhat is the trend in the Merus NV share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Merus NV. Over the past six months, its share price has outperformed the S&P500 Index by +4.79%.
As of the last closing price of $51.78, shares in Merus NV were trading +11.51% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Merus NV PE Ratio?
The Merus NV PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $51.78.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Merus NV?
Merus NV's management team is headed by:
- Anand Mehra - NEC
- Sven Lundberg - PRE
- Gregory Perry - NVC
- Cornelis Adriaan de Kruif - CTO
- Peter Silverman - GCN
- Alexander Bakker - OTH
- Andrew Joe - OTH
- Hui Liu - OTH
- Mark Iwicki - NID
- Leonard Kanavy - NID
- Paolo Pucci - NID
- Victor Sandor - NID